Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.

[1]  R. Cristescu,et al.  Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study , 2022, Journal for ImmunoTherapy of Cancer.

[2]  J. Lunceford,et al.  Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Lunceford,et al.  Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[4]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  J. Lunceford,et al.  Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors , 2022, Journal for ImmunoTherapy of Cancer.

[6]  Michael P. Morrissey,et al.  Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Sung-Bae Kim,et al.  338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study , 2021, Journal for ImmunoTherapy of Cancer.

[8]  A. Okamoto,et al.  Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Derek Y. Chiang,et al.  ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells , 2020, Molecular Cancer Research.

[10]  E. Winer,et al.  Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) , 2020 .

[11]  Fei Liu,et al.  Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells , 2019, Cellular Oncology.

[12]  D. Provencher,et al.  Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  K. Kelly,et al.  Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial , 2019, JAMA oncology.

[15]  D. Matei,et al.  Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. , 2019, Gynecologic oncology.

[16]  J. Utikal,et al.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression , 2018, British Journal of Cancer.

[17]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[18]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[19]  Lian-tang Wang,et al.  The Glycolytic Switch in Tumors: How Many Players Are Involved? , 2017, Journal of Cancer.

[20]  Peter Schmid,et al.  LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 , 2017 .

[21]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[22]  Jin-Ming Yang,et al.  Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect , 2016, Acta Pharmacologica Sinica.

[23]  A. Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[24]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Utikal,et al.  Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab , 2015, Clinical Cancer Research.

[26]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[27]  C. Meyer,et al.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.

[28]  J. Geschwind,et al.  Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.

[29]  F. Minutolo,et al.  Anticancer Agents That Counteract Tumor Glycolysis , 2012, ChemMedChem.